Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Amneal (NASDAQ: AMRX) and the best and worst performers in the generic pharmaceuticals industry.

The generic pharmaceutical industry operates on a volume-driven, low-cost business model, producing bioequivalent versions of branded drugs once their patents expire. These companies benefit from consistent demand for affordable medications, as they are critical to reducing healthcare costs. Generics typically face lower R&D expenses and shorter regulatory approval timelines compared to branded drug makers, enabling cost efficiencies. However, the industry is highly competitive, with intense pricing pressures, thin margins, and frequent legal challenges from branded pharmaceutical companies over patent disputes. Looking ahead, the industry is supported by tailwinds such as the role of AI in streamlining drug development (reverse engineering complex formulations) and manufacturing efficiency (optimize processes and remove inefficiencies). Governments and insurers' focus on reducing drug costs can also boost generics' adoption. However, headwinds include escalating pricing pressure from large buyers like pharmacy chains and healthcare distributors as well as evolving regulatory hurdles.

The 4 generic pharmaceuticals stocks we track reported a mixed Q4. As a group, revenues beat analysts’ consensus estimates by 4.8%.

Amidst this news, share prices of the companies have had a rough stretch. On average, they are down 7.6% since the latest earnings results.

Amneal (NASDAQ: AMRX)

Founded in 2002 and growing into one of America's largest generic drug producers, Amneal Pharmaceuticals (NASDAQ: AMRX) develops, manufactures, and distributes generic medicines, specialty branded drugs, biosimilars, and injectable products for the U.S. healthcare market.

Amneal reported revenues of $814.3 million, up 11.5% year on year. This print exceeded analysts’ expectations by 0.9%. Despite the top-line beat, it was still a mixed quarter for the company with an impressive beat of analysts’ full-year EPS guidance estimates but full-year revenue guidance missing analysts’ expectations.

Amneal pulled off the highest full-year guidance raise of the whole group. Still, the market seems discontent with the results. The stock is down 0.4% since reporting and currently trades at $12.83.

Is now the time to buy Amneal? Access our full analysis of the earnings results here, it’s free.

Best Q4: ANI Pharmaceuticals (NASDAQ: ANIP)

With a diverse portfolio of 116 pharmaceutical products and a growing rare disease platform, ANI Pharmaceuticals (NASDAQ: ANIP) develops, manufactures, and markets branded and generic prescription pharmaceuticals, with a focus on rare disease treatments.

ANI Pharmaceuticals reported revenues of $237.5 million, up 20.5% year on year, outperforming analysts’ expectations by 14%. The business had an exceptional quarter with a beat of analysts’ EPS and revenue estimates.

ANI Pharmaceuticals scored the biggest analyst estimates beat and fastest revenue growth among its peers. However, the results were likely priced into the stock as it’s traded sideways since reporting. Shares currently sit at $84.27.

Is now the time to buy ANI Pharmaceuticals? Access our full analysis of the earnings results here, it’s free.

Weakest Q4: Amphastar Pharmaceuticals (NASDAQ: AMPH)

Founded in 1996 and known for its expertise in complex drug formulations, Amphastar Pharmaceuticals (NASDAQ: AMPH) develops and manufactures technically challenging injectable and inhalation medications, including both generic and proprietary pharmaceutical products.

Amphastar Pharmaceuticals reported revenues of $171.2 million, flat year on year, falling short of analysts’ expectations by 1.1%. It was a disappointing quarter as it posted a significant miss of analysts’ EPS and revenue estimates.

Amphastar Pharmaceuticals delivered the weakest performance against analyst estimates and slowest revenue growth in the group. As expected, the stock is down 21.4% since the results and currently trades at $18.90.

Read our full analysis of Amphastar Pharmaceuticals’s results here.

Viatris (NASDAQ: VTRS)

Created through the 2020 merger of Mylan and Pfizer's Upjohn division, Viatris (NASDAQ: VTRS) is a healthcare company that develops, manufactures, and distributes branded and generic medicines across more than 165 countries worldwide.

Viatris reported revenues of $3.52 billion, up 8.1% year on year. This number beat analysts’ expectations by 5.2%. Overall, it was a strong quarter as it also logged a solid beat of analysts’ revenue and EPS estimates.

The stock is up 1.9% since reporting and currently trades at $16.25.

Read our full, actionable report on Viatris here, it’s free.

Market Update

Late in 2025 into early 2026, there was hand wringing around artificial intelligence. For software companies, the fear was that AI would erode pricing power and compress margins as new tools made it easier to replicate what once required expensive enterprise platforms. Crypto investors had their own version of the same anxiety: if AI agents could trade, allocate capital, and manage wallets autonomously, what exactly was the long-term value of today’s crypto infrastructure?

These concerns triggered a noticeable rotation away from these sectors and into safer havens. But markets rarely dwell on one narrative for long. Spring 2026 came, and the focus shifted abruptly from technological disruption to geopolitical risk. The US’ conflict with Iran became the dominant driver of market psychology, and when geopolitics takes center stage, the script changes quickly. Investors stop debating growth rates and start worrying about oil supply, inflation, and global stability.

Want to invest in winners with rock-solid fundamentals? Check out our Hidden Gem Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.